Search research articles
Contact Us
Filters
Showing results (771-780 of 848) with videos related to
Page
of 85
Sort By:
Future Oncology (London, England)
|
December 10, 2025
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma
Nathalie A Johnson, Pier Luigi Zinzani, Eva Domingo-Domenech, et al.
Pediatric Obesity
|
January 17, 2019
Maternal body mass index, excess gestational weight gain, and diabetes are positively associated with neonatal adiposity in the Pregnancy and Neonatal Diabetes Outcomes in Remote Australia (PANDORA) study
Danielle K Longmore, Elizabeth L M Barr, I-Lynn Lee, et al.
The Clinical Neuropsychologist
|
February 15, 2023
Using serial position effects to investigate memory dysfunction in homeless and precariously housed persons
Kristina M Gicas, Katie Benitah, Allen E Thornton, et al.
Blood
|
July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
Deborah M Stephens, Hongli Li, Heiko Schöder, et al.
Canadian Journal of Kidney Health and Disease
|
August 20, 2025
Cardiometabolic Biomarkers and Prediction of Kidney Disease Progression: The eGFR Cohort Study
Elizabeth L M Barr, Federica Barzi, Phillip Mills Kulkalgal, et al.
Blood
|
July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
Vindi Jurinovic, Robert Kridel, Annette M Staiger, et al.
Plos One
|
November 14, 2013
Personalized risk assessment of drug-related harm is associated with health outcomes
Andrea A Jones, Fidel Vila-Rodriguez, William J Panenka, et al.
Diabetologia
|
September 10, 2020
Associations of gestational diabetes and type 2 diabetes during pregnancy with breastfeeding at hospital discharge and up to 6 months: the PANDORA study
Danielle K Longmore, Elizabeth L M Barr, Alyce N Wilson, et al.
Blood
|
February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Constantine S Tam, John N Allan, Tanya Siddiqi, et al.
Blood Advances
|
October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
Brian T Hill, Shuo Ma, Clive S Zent, et al.
Page
of 85
Search research articles
Search
Showing results (771-780 of 848) with videos related to
Sort By:
Page
of 85
Future Oncology (London, England)
|
December 10, 2025
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma
Nathalie A Johnson, Pier Luigi Zinzani, Eva Domingo-Domenech, et al.
Pediatric Obesity
|
January 17, 2019
Maternal body mass index, excess gestational weight gain, and diabetes are positively associated with neonatal adiposity in the Pregnancy and Neonatal Diabetes Outcomes in Remote Australia (PANDORA) study
Danielle K Longmore, Elizabeth L M Barr, I-Lynn Lee, et al.
The Clinical Neuropsychologist
|
February 15, 2023
Using serial position effects to investigate memory dysfunction in homeless and precariously housed persons
Kristina M Gicas, Katie Benitah, Allen E Thornton, et al.
Blood
|
July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
Deborah M Stephens, Hongli Li, Heiko Schöder, et al.
Canadian Journal of Kidney Health and Disease
|
August 20, 2025
Cardiometabolic Biomarkers and Prediction of Kidney Disease Progression: The eGFR Cohort Study
Elizabeth L M Barr, Federica Barzi, Phillip Mills Kulkalgal, et al.
Blood
|
July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
Vindi Jurinovic, Robert Kridel, Annette M Staiger, et al.
Plos One
|
November 14, 2013
Personalized risk assessment of drug-related harm is associated with health outcomes
Andrea A Jones, Fidel Vila-Rodriguez, William J Panenka, et al.
Diabetologia
|
September 10, 2020
Associations of gestational diabetes and type 2 diabetes during pregnancy with breastfeeding at hospital discharge and up to 6 months: the PANDORA study
Danielle K Longmore, Elizabeth L M Barr, Alyce N Wilson, et al.
Blood
|
February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Constantine S Tam, John N Allan, Tanya Siddiqi, et al.
Blood Advances
|
October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
Brian T Hill, Shuo Ma, Clive S Zent, et al.
Page
of 85